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Abstract
Background: Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last
decade. The objective of this study is to prepare a document providing recommendations for the
use of SYSADOA in osteoarthritis (OA).
Methods:  The following interventions were taken into consideration: avocado/soybean
unsaponifiables, chondroitin sulfate, diacereine, glucosamine sulfate, hyaluronic acid, oral calcitonin,
risedronate, strontium ranelate. Recommendations were based on the GRADE (Grading of
Recommendations Assessment, Development and Evaluation) system. The GRADE system is based
on a sequential assessment of the quality of evidence, followed by assessment of the balance
between benefits versus downsides and subsequent judgment about the strength of
recommendations.
Results: Chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and
hyaluronic acid have demonstrated pain reduction and physical function improvement with very
low toxicity, with moderate to high quality evidence. Even if pre-clinical data and some preliminary
in vivo studies have suggested that oral calcitonin and strontium ranelate could be of potential
interest in OA, additional well-designed studies are needed.
Conclusion: In the benefit/risk ratio, the use of chondroitin sulfate, diacereine, glucosamine
sulfate, avocado/soybean unsaponifiables and hyaluronic acid could be of potential interest for the
symptomatic management of OA.
Background
Osteoarthritis (OA) is a progressive disorder characterized
by destruction of articular cartilage and subchondral bone
associated with synovial changes [1,2]. This degenerative
condition affects aging men and women [3]. The two
most affected location for pain and physical disability in
adults are hip and knee [4]. Because of its important prev-
alence worldwide, OA represents a huge burden in terms
of individual, as well as public health resources utilization
[5]. Pharmacological and non-pharmacological proce-
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dures have demonstrated their efficacy to stop or decrease
progression of this condition. Among pharmacological
treatments, symptomatic slow-acting drugs have been
largely studied over the last decade.
Most countries face common challenges in delivering con-
sistent, appropriate and high quality health care standards
within the limits of available resources. Clinical guide-
lines are one of the most important options to support
and promote good clinical practices, and subsequently to
make patient care more effective and efficient. However,
to ensure that clinical guidelines actually meet this objec-
tive, they should follow a strict, validated methodology.
Over the last decade, several scientific societies involved
in OA produced guidelines for the management of hip,
knee and hand to improve quality and effectiveness of
patients care [6-11]. Nevertheless, the most recent ver-
sions which have been prepared by prestigious institu-
tions, such as the American College of Rheumatology (ACR)
or the European League Against Rheumatism (EULAR) do
not include the latest original research papers [12-28].
Furthermore, the recommendations established on the
same topic by these two groups often differ. Part of the
reasons are the lack of evidence, different interpretation of
evidence, unsystematic guideline development methods,
influence of professional bodies, cultural and socio-eco-
nomic factors and differences in health care systems [29-
31].
For all these reasons the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
experts found appropriate to build their own recommen-
dations for the use of symptomatic slow-acting drugs in
osteoarthritis (SYSADOA) based on the GRADE system
[32,33]. The acronym of GRADE stands for Grading of
Recommendations Assessment, Development and Evalu-
ation.
The GRADE system is based on a sequential assessment of
the quality of evidence, followed by assessment of the bal-
ance between benefits versus downsides and subsequent
judgment about the strength of recommendations.
Because frontline consumers of recommendations will be
most interested in the best course of action, the GRADE
system places the strength of the recommendation first,
followed by the quality of the evidence. Separating the
judgments regarding the quality of evidence from judg-
ments about the strength of recommendations is a critical
and specific feature of this new grading system.
GRADE has two level of recommendation: strong and
weak (Table 1). As a matter of fact, recommendations to
administer, or not administer, an intervention, should be
based on trade-offs between benefits and risks, burden
and, where possible, costs. If benefits outweigh risks and
burden, experts will recommend that clinicians offer a
treatment to patients sustaining typical symptoms of the
disease. The uncertainty associated with the trade-off
between the benefits and risks and burdens will determine
the strength of recommendations.
Methods
A systematic and exhaustive search of the meta-analysis
and randomized controlled trials published from 1950
until December 2007 has been undertaken, using several
tools, such as Medline, Old Medline, Embase, CINAHL,
Science Citation Index through Web of Science, Allied
Complementary Medicine and Cochrane Library data-
bases. The search in the Cochrane Library included the
Cochrane Reviews, Abstracts of Quality Assessed System-
atic Reviews, The Cochrane Controlled Trial Register, NHS
Economic Evaluation Database, Health Technology
Assessment Database and NHS Economic Evaluation Bib-
liography Details Only.
Table 1: Strength of guideline recommendations, consensus-based statements, and implication to quality of evidence
Recommendation or statement Description in GRADE approach Interpretation
Strong guideline recommendation We recommend (should) 1. Most individuals should receive the intervention, assuming that 
they have been informed about and have understood its benefits, 
harms and burden.
2. Most individuals would want the recommended course of action 
and only a small proportion would not.
3. The recommendation could unequivocally be used for policy 
making.
Weak guideline recommendation We suggest (might) 1. The majority of individuals would want to suggested course of 
action, but an appreciable proportion would not.
2. Values and preferences vary widely.
3. Policy making will require extensive debates and involvement of 
many stakeholders.BMC Musculoskeletal Disorders 2008, 9:165 http://www.biomedcentral.com/1471-2474/9/165
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Quality of the evidence has been assessed using the grade
four-category system (high, moderate, low and very low
quality) (Table 2).
Factors that are considered in classifying evidence are: the
study design and rigour of its execution, the consistency of
results and how well the evidence can be directly applied
to patients, interventions, outcomes and comparator.
Other important factors are whether the data are sparse or
imprecise and whether there is potential for reporting
bias. Using this approach, assessments of the quality of
evidence for each important outcome take into account
the study design, limitations of the studies, consistency of
the evidence across studies, the directness of the evidence,
and the precision of the estimate.
Obviously, all outcomes (e.g. pain, function, NSAIDS
consumption, carry-over effect, harm, global patient satis-
faction, use of walking aids, structure modification, and
evaluation by the GP) have not the same importance. The
importance of each outcome has then been scored (10
mm VAS) independently by each expert. Only outcomes
considered as important (VAS > 6 mm) by all experts were
discussed in these recommendations.
For each intervention considered, the panel formulated a
consensus recommendation based on the panel members'
judgments regarding the balance between the benefits,
harms (adverse effects), burdens (e.g., taking medication
daily), costs, and values and preferences (the desirability
or preference that individuals exhibit for a particular out-
come) of the intervention. Source of funding has not been
considered. Then, recommendations have been classified
as "strong" or "weak."
Results
The experts considered that pain, function and harm are
of primary interest in the evaluation of SYSADOA.
The following interventions were taken into considera-
tion:
- Avocado/soybean unsaponifiables [34-36].
- Chondroitin sulfate [37-40].
- Diacereine [41,42].
- Glucosamine sulfate [38,39,43-45].
- Hyaluronic acid [46-52].
- Oral calcitonin [53].
- Risedronate [54,55].
- Strontium ranelate [56].
Following the GRADE system, the study design for all tri-
als included in the review of evidence for chondroitin sul-
fate, diacereine, glucosamine sulfate, hyaluronic acid and
risedronate was randomised controlled trial which is
scored as a high type of evidence. As requested from the
methodology of GRADE, study quality was also assessed
by reviewing whether the studies had limitations or flaws.
The following limitations were noted, leading frequently
to a decrease in the quality of evidence: methods of ran-
domisation were not clearly reported, allocation conceal-
ment was not reported or unclear, some trials were single-
blinded and frequently the method of blinding was not
reported in detail, incomplete descriptions of withdrawals
and dropouts were reported, analyses were based on the
per protocol or completer population and not on the
intention-to-treat population, heterogeneity not tested in
meta-analysis, large heterogeneity between meta-analyses
statistically significant differences were reported at base-
line between treatment and control groups, different
severity of knee OA patients were included, large results
discrepancies (e.g. between studies or between meta-anal-
ysis and large recent studies), nature of the placebo com-
parator, very few number of patient included, post-hoc
analysis.
Quality evidence could also decrease when considering
meta-analysis (e.g. moderate and high heterogeneity
between RCT, or heterogeneity between meta-analyses).
Table 2: Quality of the quality evidence, definitions and underlying methodology
Grade Definition Underlying Methodology
High Further research is very unlikely to change our confidence in the estimate of 
effect
RCT or meta-analysis
Moderate Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate
Downgraded RCTs or upgraded observational studies
Low Further research is very likely to have an important impact on our confidence 
in the estimate of effect an its likely to change the estimate
Well-done observational studies with control groups
Very low Any estimate of effect is very uncertain Others (e.g., case reports or case series)BMC Musculoskeletal Disorders 2008, 9:165 http://www.biomedcentral.com/1471-2474/9/165
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The summary of the grading recommendation is summa-
rized in table 3 and the text below summarizes the most
important data for each compound.
1. Avocado/soybean unsaponifiables
Three RCTs have been selected for our recommendations.
The first one is a 3-month, prospective, randomized, dou-
ble-blind, placebo-controlled trial evaluating the efficacy
of avocado/soybean unsaponifiables (300 mg/day) in
terms of NSAID use reduction [34]. Secondary efficacy cri-
teria were the visual analogic scale pain score and the
Lequesne index. After 3 months, the functional index
showed a significantly greater improvement in the active
drug group (-2.3 +/- 2.6) than in the placebo group (-1.0
+/- 2.6) (p < 0.01). However, pain scores over time were
similar in the two groups.
The second study (n = 260), of the same duration, showed
that avocado/soybean unsaponifiables (300 or 600 mg/
day) significantly reduced the Lequesne index (secondary
outcome) compared to placebo [35]. After 6 months of
follow-up, the mean (SD) Lequesne score decreased from
9.6 +/- 2.5 to 5.5 +/- 3.6 in the avocado/soybean unsapon-
ifiables 300 mg/day, from 9.8 +/- 2.7 to 6.5 +/- 3.5 in the
avocado/soybean unsaponifiables 600 mg/day and from
9.8 +/- 2.4 to 7.8 +/- 3.4 in the placebo group (p < 0.01
between placebo and the two avocado/soybean unsapon-
ifiables groups).
The third RCT included 164 patients with primary OA of
the knee (n = 114) or hip (n = 50) with a 6-month treat-
ment period and a 2-month post-treatment follow-up
[36]. The results showed that avocado/soybean unsapon-
ifiables (300 or 600 mg/day) significantly reduced the
Lequesne index (primary outcome) and the pain score
(VAS scale) compared to placebo. After 6 months of fol-
low-up, the mean (SEM) Lequesne score decreased from
9.7 +/- 0.3 to 6.8 +/- 0.4 in the avocado/soybean unsapon-
ifiables and from 9.4 +/- 0.3 to 8.9 +/- 0.4 in the placebo
group (p < 0.001). Pain decreased from 56.1 +/- 1.6 mm
to 35.3 +/- 2.3 in the avocado/soybean unsaponifiables
and from 56.1 +/- 1.8 to 45.7 +/- 2.6 in the placebo group
(p = 0.003).
In these 3 trials, avocado/soybean unsaponifiables were
well tolerated.
2. Chondroitin sulfate
Four meta-analyses have been selected. However, two of
them, showing a significant effect of chondroitin sulfate
compared to placebo, were outdated since they were
issued before the appearance of major recent trials
[37,38]. One of them is also difficult to use since the
authors evaluated chondroitin sulfate together with glu-
cosamine sulfate [39].
In the last meta-analysis, 20 trials (3846 patients) were
included [40]. The meta-analysis identified a significant
beneficial effect of chondroitin sulfate on pain, with an
effect size of -0.75 (-0.99 to -0.50). However, the hetero-
geneity between trials was high (I2 = 92%). When the
authors restricted the analysis to the 3 trials with large
sample sizes and an intention-to-treat analysis, the effect
size was -0.03 (-0.13 to 0.07; I2 = 0%) and corresponded
to a difference of 0.6 mm on a 10-cm visual analogic scale.
However, this restricted analysis included one study with
an exceptionally high placebo response rate, one study
that was only published as an abstract.
At last, a meta-analysis of 12 trials showed a pooled rela-
tive risk of 0.99 (0.76 to 1.31) for any adverse event
between chondroitin sulfate and placebo [40].
3. Diacerein
Two meta-analyses have been included.
The fist one included 19 studies (search date 1985–2004)
[41]. Diacerein was significantly superior to placebo to
reduce pain and improve function during the active treat-
ment phase (Glass score 1.50 [0.80–2.20]). Moreover,
diacerein showed a carryover effect, persisting up to 3
months after treatment, with a significant analgesic-spar-
ing effect during the follow-up period (Glass score 2.06
Table 3: Recommendations taking into account the balance of benefit (pain reduction and function improvement) and harm (adverse 
event)
Product Grade of recommendation Quality evidence Balance benefit to harm
Avocado/soybean unsaponifiables Strong Moderate Avocado/soybean unsaponifiables advantageous
Chondroitin sulfate Strong Moderate Chondroitin sulfate advantageous
Diacereine Strong Moderate Diacereine advantageous
Glucosamine sulfate Strong Moderate Glucosamine sulfate advantageous
Hyaluronic acid Strong Moderate Hyaluronic acid advantageous
Oral calcitonin Weak Low Calcitonin not advantageous
Risedronate Strong High Risedronate not advantageous
Strontium ranelate Weak Very low Strontium ranelate advantageousBMC Musculoskeletal Disorders 2008, 9:165 http://www.biomedcentral.com/1471-2474/9/165
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[0.66 to 3.46]). Nevertheless, it should be pointed out
that heterogeneity was not tested in this meta-analysis.
The second one included 7 studies (search date 1966–
2004) with 2069 participants [42]. The results of the
meta-analysis showed a small, consistent, beneficial effect
of diacerein in the treatment of OA. When compared to
placebo, pain on a visual analogic scale (0–100 mm)
showed a statistically significant difference in favour of
diacerein (weighted mean differences of -5.16 [-9.75 to -
0.57]); but the heterogeneity analysis result was impor-
tant (p = 0.04). No significant effect of diacereine was
observed on the Lequesne index for function compared to
placebo, with homogeneity in all results. The most fre-
quent adverse event was diarrhoea. 459 participants
among 1083 participants that received diacerein (42%)
were affected. 18% in the treatment group compared with
13% in the placebo group withdrew due to adverse events.
4. Glucosamine sulfate
Five meta-analysis and systematic reviews were included.
Three groups of systematic reviews and meta-analyses
emerged:
▪ A Cochrane Review, first published in 2001 and updated
in 2005 [43], that includes every relevant glucosamine tri-
als but studies published in 2006 and 2007. This meta-
analysis remains the only one that includes all reference
(NSAIDs)-controlled trials. In addition, it provides an
evaluation on safety aspects.
▪ Meta-analyses by a group in Boston. The first was pub-
lished in 2000 and is clearly outdated since it was issued
before the appearance of all recent and most relevant trials
[38]. However, Vlad et al. updated their meta-analysis in
2007 and this included all relevant placebo-controlled
glucosamine trials [44].
▪ Systematic reviews and meta-analyses performed by the
group in Liege. The first was published in 2003 and had
the merit to be the first to include the glucosamine sulfate
long-term trials [39]. However, aside not being up to date,
it is also difficult to use for the assessment of glucosamine
sulfate studies on the symptoms of OA, since these trials
are evalutated together with those of chondroitin sulfate.
Nevertheless, Reginster updated this group's systematic
review and meta-analysis in 2007 in an editorial of the
meta-analysis by Vlad et al., using in his approach the piv-
otal trials of prescription glucosamine sulfate [44,45].
Three systematic reviews and meta-analyses have been
used in the present assessment [43-45].
In the Cochrane review, the 20 analyzed RCTs found glu-
cosamine favoured placebo with a 28% (change from
baseline) improvement in pain (standardized mean dif-
ference of -0.61 [-0.95 to -0.28] and a 21% (change from
baseline) improvement in function using the Lequesne
index (standardized mean difference of -0.51 [-0.96 to -
0.05]) [43].
Vlad et al. also reported a significant effect of glucosamine
sulfate for pain improvement (effect size of 0.35 [0.14 to
0.56]) [44]. However, heterogeneity was high among the
15 RCTs included in their meta-analysis (I2 = 80%).
Reginster based his meta-analysis only on 3 specific piv-
otal trials of glucosamine sulfate [45]. Pivotal trials are
high-quality studies used by Health Authorities to assess
the efficacy and safety of a prescribed medication in order
to grant the marketing authorisation. The assessments of
WOMAC pain and WOMAC function provide a signifi-
cant beneficial effect of glucosamine sulfate compared to
placebo (effect size of 0.27 [0.12 to 0.43]) and 0.33 [0.17–
0.48], respectively), without heterogeneity (I2 = 0%).
At least, glucosamine sulfate was as safe as placebo, in
terms of subjects reporting adverse reactions (RR = 0.97
[0.88 to 1.08]) [43].
5. Hyaluronic Acid
Seven systematic reviews have been included in this
assessment.
Analysis of these meta-analyses showed discrepancies
between systematic reviews/meta-analyses of the efficacy
and safety of hyaluronic acid (HA) therapy in the treat-
ment of osteoarthritis [46-52].
Out of the 11 RCTs included in a meta-analysis, it has
been demonstrated that the 100-mm visual analogic scale
differences between therapy and placebo injection was 4.4
(1.1 to 7.2) at 1 week, 17.7 (7.5 to 28.0) at 5 to 7 weeks,
18.1 (6.3 to 29.9) at 8 to 12 weeks, and 4.4 (-15.3 to 24.1)
at 15 to 22 weeks [51]. Another meta-analysis, including
22 RCTs, showed that patients who received the interven-
tion treatment experienced a reduction in pain during
movement: the mean difference on a 100-mm visual ana-
logue scale was -3.8 mm (-9.1 to 1.4 mm) after 2–6 weeks,
-4.3 mm (-7.6 to -0.9) after 10–14 weeks and -7.1 mm (-
11.8 to -2.4) after 22–30 weeks [47]. However, this effect
was not considered as being clinically meaningful [47].
Another meta-analysis showed that, from the 22 studies
included, the pooled effect size for hyaluronic acid was
0.32 (0.17 to 0.47) when considering pain reduction but
with a significant heterogeneity among studies (P < .001)
[48].
Interestingly, the reasons for inconsistency between sys-
tematic reviews have been recently searched by J. Camp-BMC Musculoskeletal Disorders 2008, 9:165 http://www.biomedcentral.com/1471-2474/9/165
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bell et al. [57]. They identified inclusion of different
controlled trials as a result of different search strategies
and selection criteria, differences in the outcome meas-
ures and time points selected for extraction; and different
statistical methods for data synthesis, which resulted in
conflicting estimates of therapeutic effect. Anyway, the
authors concluded that although the overall quality was
moderate, there were net benefits (pain reduction and
physical function) in favour of HA compared to placebo
with low risk of harm.
6. Oral calcitonin
One RCT has been included. In this small randomized,
double-blind trial, patients received either placebo (n =
18), 0.5 mg of oral salmon calcitonin (n = 17), or 1 mg of
oral salmon calcitonin (n = 18) daily for 84 days [53]. No
significant improvements were observed at the end of the
study between patients on placebo or oral calcitonin, in
the Lequesne index (secondary outcome).
7. Risedronate
Two RCTs have been included in this analysis.
The first trial included 2483 patients (placebo, 5 or 15 mg
risedronate) in a 2-year study [54]. No significant effect of
risedronate has been observed in the WOMAC score, com-
pared to placebo. No increase in the number of adverse
events was demonstrated for risedronate compared with
placebo.
In the second study, 285 patients were randomized to
once-daily risedronate (5 mg or 15 mg) or placebo, in a 1-
year prospective, double-blind, placebo-controlled trial
[55]. Those receiving risedronate showed no improve-
ment of the WOMAC index, compared to placebo. Both
doses of risedronate were well tolerated.
8. Strontium ranelate
One RCT has been included.
This RCT is a post-hoc analysis of two trials aiming at
assessing the efficacy and safety of strontium ranelate in
the treatment of postmenopausal osteoporosis [56]. The
results showed that among 399 osteoporotic women with
concomitant radiological spinal OA, significantly more
patients in the strontium ranelate group experienced an
improvement in back pain after 3 years (secondary analy-
sis), compared with placebo (p = 0.03).
Discussion
In the light of these results, some SYSADOA have a posi-
tive risk benefit balance for patients with OA. As a matter
of fact, chondroitin sulfate, diacereine, glucosamine sul-
fate, avocado/soybean unsaponifiables and hyaluronic
acid have demonstrated pain reduction and physical func-
tion improvement with very low toxicity, with moderate
to high quality evidence. The only treatment with a sub-
stantial highest level of adverse events was diacerheine.
The most frequent adverse effect was mild to moderate
diarrhoea, which usually appeared at an early stage during
treatment and resolved on continuing treatment. How-
ever, this adverse event did not result in treatment inter-
ruption in the majority of the patients.
Based on our research, there are only two treatments that
are "weakly" recommended. Indeed, even if pre-clinical
data and some preliminary in vivo studies have suggested
that oral calcitonin and strontium ranelate could be of
potential interest in OA, additional well-designed studies
are needed.
It should be pointed out that some meta-analysis, even
with positive results for the treatment compared to pla-
cebo, have strong evidence of heterogeneity and, with
consequences, a lowest quality evidence for the treatment,
following the GRADE recommendation (e.g. reduced
from "high" to "moderate").
Results of the GAIT trial are also of interest and deserve
special comments as this study involves glucosamine and
chondroitin [58]. This National Institutes of Heath spon-
sored study examined placebo versus glucosamine hydro-
chloride (500 mg three times daily) versus chondroitin
sulfate (400 mg three times daily) versus the combination
of glucosamine and chondroitin versus celecoxib (200
mg/day) in a parallel, blinded 6 month multicenter study
of response in knee OA. The primary efficacy variable was
a 20% improvement in knee pain from baseline to 24
weeks. Overall, glucosamine and chondroitin sulfate were
not significantly better than placebo in reducing knee
pain by 20 percent. However, for patients with moderate-
to-severe pain at baseline, the rate of response (OMER-
ACT-OARSI criteria) was significantly higher with com-
bined therapy than with placebo (79.2% vs. 54.3%, P =
0.002). The high placebo response (60.1%) is of
unknown significance but might explain the findings of
the GAIT trial. As a matter of fact, if placebo is effective in
60 percent of patients, it could be difficult for other treat-
ments to surpass this mark. At least, this study used the
glucosamine hydrochloride 500 mg three times daily
comparted to glucosamine sulfate 1500 once daily in the
most positive trials,
It should be acknowledged, however, that the size effect in
pain and physical improvement is only considered from
small to moderate. At least, the duration of the RCT differs
widely (3 months to 3 years), within and between treat-
ments, making the interpretation sometime more diffi-
cult.BMC Musculoskeletal Disorders 2008, 9:165 http://www.biomedcentral.com/1471-2474/9/165
Page 7 of 9
(page number not for citation purposes)
It should also be pointed out that some potential treat-
ments have only been assessed in one site and that, partly
because of the difference in the physiopathology between
hip and knee osteoarthritis, results obtained at the level of
the knee can not be extrapolated to the hip. For example,
it has been shown in one study that glucosamine sulfate
appears to be ineffective in hip osteoarthritis [59].
At least, although we have used the GRADE approach to
rate the quality of evidence and strength of recommenda-
tion, the need for judgment is still required. Indeed, RCTs
or meta-analysis of the same product could have impor-
tant methodological differences that may impact on the
results. At least, even if the use of risk/benefit ratio is of
great potential interest, it still needs further validation. It
should also be pointed out, as a limitation of this work,
that studies were not blinded and, consequently, some
experts reviewed the quality of their own works.
Conclusion
In conclusion, in the benefit/risk ratio, the use of chon-
droitin sulfate, diacereine, glucosamine sulfate, avocado/
soybean unsaponifiables and hyaluronic acid could be of
potential interest for the symptomatic management of
OA.
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